Search
Search Results
-
Pharmacokinetics of the Novel Nonsteroidal Mineralocorticoid Receptor Antagonist Ocedurenone (KBP-5074) in Individuals with Moderate Hepatic Impairment
Background and ObjectivesOcedurenone (KBP-5074) is a novel nonsteroidal mineralocorticoid receptor antagonist that has demonstrated safety and...
-
Estimation of linezolid exposure in patients with hepatic impairment using machine learning based on a population pharmacokinetic model
PurposeTo investigate the pharmacokinetic changes of linezolid in patients with hepatic impairment and to explore a method to predict linezolid...
-
Physiologically based pharmacokinetic modeling of apixaban to predict exposure in populations with hepatic and renal impairment and elderly populations
BackgroundApixaban is a factor Xa inhibitor with a limited therapeutic index that belongs to the family of oral direct anticoagulants. The...
-
A standard dose of linezolid puts patients with hepatic impairment at risk of overexposure
PurposeThe purpose of this retrospective observational study conducted in patients with hepatic impairment was to assess the variability of linezolid...
-
Gut Microbiota-Mediated Alterations of Hippocampal CB1R Regulating the Diurnal Variation of Cognitive Impairment Induced by Hepatic Ischemia–Reperfusion Injury in Mice
Patients suffering from hepatic ischemia–reperfusion injury (HIRI) frequently exhibit postoperative cognitive deficits. Our previous observations...
-
Simulating Healthy Participant Pharmacokinetics for Renal and Hepatic Impairment Studies: Retrospective Assessment of the Approach
The recruitment of a parallel, healthy participants (HPs) arm in renal and hepatic impairment (RI and HI) studies is a common strategy to assess...
-
Leveraging Prior Healthy Participant Pharmacokinetic Data to Evaluate the Impact of Renal and Hepatic Impairment on Ritlecitinib Pharmacokinetics
AbstractRitlecitinib is a selective, covalent, irreversible inhibitor of Janus kinase 3 (JAK3) and the tyrosine kinase expressed in hepatocellular...
-
Phase 1 Study to Assess the Safety and Pharmacokinetics of Elexacaftor/Tezacaftor/Ivacaftor in Subjects Without Cystic Fibrosis With Moderate Hepatic Impairment
Background and ObjectiveElexacaftor/tezacaftor/ivacaftor is highly effective in treating people with cystic fibrosis (pwCF) who have ≥ 1 responsive...
-
Physiologically Based Pharmacokinetic Modeling for Prediction of 5-FU Pharmacokinetics in Cancer Patients with Hepatic Impairment After 5-FU and Capecitabine Administration
Purpose5-fluorouracil (5-FU) and its prodrug capecitabine are commonly prescribed anti-tumor medications. We aimed to establish physiologically based...
-
Hepatic Impairment Physiologically Based Pharmacokinetic Model Development: Current Challenges
PurposeThis review summarizes the development processes of hepatic impairment (HI) PBPK models, examines current challenges, and proposes potential...
-
Physiologically based pharmacokinetic combined BTK occupancy modeling for optimal dosing regimen prediction of acalabrutinib in patients alone, with different CYP3A4 variants, co-administered with CYP3A4 modulators and with hepatic impairment
PurposeTo develop a mathematical model combined between physiologically based pharmacokinetic and BTK occupancy (PBPK-BO) to simultaneously predict...
-
Physiologically based pharmacokinetic modelling to predict the clinical effect of CYP3A inhibitors/inducers on esaxerenone pharmacokinetics in healthy subjects and subjects with hepatic impairment
PurposeEsaxerenone is a novel, oral, nonsteroidal treatment for hypertension. Physiologically based pharmacokinetic (PBPK) modelling was performed to...
-
Impact of Organ Impairment on the Pharmacokinetics of Therapeutic Peptides and Proteins
The kidneys and liver are major organs involved in eliminating small-molecule drugs from the body. Characterization of the effects of renal...
-
Salvianolic acid B suppresses hepatic fibrosis by inhibiting ceramide glucosyltransferase in hepatic stellate cells
UDP-glucose ceramide glucosyltransferase (UGCG) is the first key enzyme in glycosphingolipid (GSL) metabolism that produces glucosylceramide...
-
Obesity aggravated hippocampal-dependent cognitive impairment after sleeve gastrectomy in C57/BL6J mice via SIRT1/CREB/BDNF pathway
Postoperative cognitive dysfunction (POCD) is characterized by cognitive impairments following anesthesia/surgery, but the role of obesity and the...
-
Serum level of YWHAG as a diagnostic marker of cognitive impairment in Parkinson’s disease patients
BackgroundIdentifying reliable biomarkers for early detection and prediction of cognitive impairment in Parkinson’s disease (PD) is crucial for...
-
Aberrant stability of brain functional architecture in cirrhotic patients with minimal hepatic encephalopathy
To investigate the stability changes of brain functional architecture and the relationship between stability change and cognitive impairment in...
-
Ferrous sulfate reverses cerebral metabolic abnormality induced by minimal hepatic encephalopathy
Orally administered ferrous iron was previously reported to significantly improve the cognition and locomotion of patients with minimal hepatic...
-
The role of hypoxia-inducible factor 1α in hepatic lipid metabolism
AbstractChronic liver disease is a major public health problem with a high and increasing prevalence worldwide. In the progression of chronic liver...
